Literature DB >> 16920044

The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma.

Amir H Shemirani1, Gizella Haramura, Zsuzsa Bagoly, László Muszbek.   

Abstract

The first step in the activation of blood coagulation factor XIII (FXIII) is the proteolytic cleavage of the potentially active A subunit (FXIII-A) by thrombin at Arg37-Gly38. Both fibrin formation and FXIII-A Val34Leu polymorphism influence the rate of proteolytic activation of purified factor XIII, however their relative importance and interaction in determining the time of onset and the rate of FXIII activation in whole plasma have not yet been explored. In the present study it was shown that in plasma, fibrin formation preceded the truncation of FXIII-A by thrombin, the activation process took place exclusively on the surface of newly formed fibrin and activated FXIII remained associated with the fibrin clot. The time of fibrin formation closely correlated with the time of FXIII activation, while there was no significant relationship between the time of FXIII activation and FXIII-A Val34Leu genotype. However, in the case of Leu34 variant the lag phase between fibrin formation and FXIII-A truncation was significantly shorter than in the case of Val34 variant. The results suggest that in whole plasma the onset of FXIII activation is determined by fibrin formation, while the rate of activation is modulated by Val34Leu polymorphism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920044     DOI: 10.1016/j.bbapap.2006.06.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Impaired factor XIII activation in patients with congenital afibrinogenemia.

Authors:  Françoise Bridey; Claude Négrier; Cedric Duval; Robert Ariëns; Philippe de Moerloose; Alessandro Casini
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 2.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

3.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

4.  Coagulation Factor XIII Val34Leu Polymorphism in the Prediction of Premature Cardiovascular Events-The Results of Two Meta-Analyses.

Authors:  Beata Sarecka-Hujar; Danuta Łoboda; Elżbieta Paradowska-Nowakowska; Krzysztof S Gołba
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

5.  The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.

Authors:  James R Byrnes; Clare Wilson; Anthony M Boutelle; Chase B Brandner; Matthew J Flick; Helen Philippou; Alisa S Wolberg
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.